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Introduction
Cerebral venous thrombosis (CVT) represents only about 0.5-1 % 
of all strokes [1]. The incidence is estimated to be 2-4 per million per 
year, but the number is probably higher due to undiagnosed cases [1,2]. 
CVT occurs most often in the 3rd decade of life and then affects mostly 
women, but among children and elderly patients there is no difference 
concerning sexes [1]. 
CVT has the best prognosis at a young age without severe 
neurological deficits, such as hemiparesis, epileptic seizures and 
coma, or other co-morbidity such as cancer and serious infection [3]. 
A prospective multi-center study showed that 75% of patients with 
CVT were women with a mean age of 34 years and the best prognosis 
was found for women with risk factors like hormonal contraception, 
pregnancy and maternity [4].
Pro-thrombotic causes are found in about 85% of patients with 
CVT and include hormonal, genetic and acquired hematologic, 
inflammatory or immunologic causes, infections, cancer and other 
specific causes while about 15% are considered to be idiopathic [5]. 
Symptoms of CVT are usually increasing headache, blurred vision 
and acute focal neurological disturbances of function, such as paresis 
and focal seizures. Magnetic resonance imaging (MRI) with venous 
angiography is the gold standard for the diagnosis of CVT and is 
superior to computer tomography (CT), which is found negative in 10-
30% [6].
Symptoms of Graves’ disease are goiter, exophthalmos and 
ophthalmopathy (staring eyes) and skin changes, such as pre-tibial 
myxedema with thickened, orange-skin similar areas which are itching 
or hyper pigmented. Muscle weakness, weight changes, tremor, 
perspiration, nervousness, irritability, intolerance to heat, tachycardia 
and atrial fibrillation are symptoms that may occur due to Graves’ 
disease or other hyperthyroidism [7]. 
Hyperthyroidism is not a well-known risk factor for CVT. Our case 
report is a young woman who developed life-threatening CVT after 
Graves’ disease. We have further reviewed the literature concerning 
CVT and hyperthyroidism. 
A 17 year old girl, non-smoker, had used the hormonal 
contraception Mercilon (150 µg desogestrel and 20 µg etinylestradiol) 
for two years without any medical problems. After several weeks of 
irritability, tiredness, weight-gain, intolerance to heat, slight diarrhea, 
development of goiter and itching pre-tibial myxedema, Graves’ disease 
was diagnosed with free thyroxin (fT4)83.9 pmol/l (reference 12.6-21.0), 
TSH <0.01 mU/l (reference 0.51-4.3) and thyroid-receptor antibodies 
>40 IU/l (reference <1.5). After start of treatment with carbimazole she 
was discharged from the hospital, but on the same day she developed 
right occipital headache, pain in the neck and nausea. Four days later, 
she had a transient hemiparesis and focal seizures in her left hand. On 
the fifth day she was admitted to our department after recurrent and 
persisting left hemiparesis and lost consciousness due to generalized 
seizures. Her pupils were dilated, not reacting to light and Glasgow 
Coma Scale score at admittance was 3 points. She was intubated and 
propofol-narcosis was started due to no response to diazepam. MRI 
showed extensive thrombosis in the sagittal sinus, the right transversus 
sinus, the sigmoid sinus and the proximal right jugular vein (Figures 
1 and 2) with venous infarction (Figure 3) in the right parietal region. 
Two minor bleedings were present in the right temporal lobe because 
of stasis (Figure 4). The left sinus transversus was atretic. She was 
treated with dalteparin, adjusted after anti-factor-X a measurements 
in plasma, four hours after the last injection with the level-aim between 
0.6-1.0 IU/ml (reference 0.00-0.01). She slightly recovered over weeks, 
but developed significant bilateral exophthalmos. Anti-thrombin, 
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were women. Graves’ disease was present among 21 of the 35 patients 
and 17 of these were women. 
Discussion
The predominance of women and young age are compatible with 
results of other studies of CVT [3] and earlier review articles about 
CVT and hyperthyroidism [30,36]. The prevalence of CVT is 1,7% 
for thyroid morbidity, 34,1% for pro-thrombotic conditions (anti-
thrombin III deficiency, protein-S- or protein-C deficiency, anti-
phospholipid syndrome, activated protein-C resistance, factor V 
Leiden mutation, pro-thrombin G20210A mutation) and 53,3% for 
use of oral hormonal contraception [37]. However, as the overview is 
only listing case studies, it is not possible to draw conclusions about 
frequency of coagulation deficiencies, infections or the use of oral 
contraception as blood samples were not standardized screened and 
cases were not standardized reported. 
protein-C, protein-S, Factor V Leiden mutation and pro-thrombin 
G20210A polymorphism were normal. The metylentetrahydrofolat 
reductase (MTHFR) gene was heterozygote. 
After two months, the NIHSS score was 0 and the patient continued 
her education as planned. After six months, anti-epileptic treatment 
was already discontinued and control MRI-angiography showed 
recanalization. Anticoagulation was discontinued. After eight months, 
thyroidectomy was performed due to non-optimal controlled Graves’ 
disease by medical treatment alone. She was also operated for bilateral 
exophthalmos. The patient has given written consent for publishing her 
case and the images.
Review of the Literature
In addition to our patient, we found 34 other cases of CVT and 
hyperthyroidism (Table 1). The mean age is 32 years. The youngest 
patient was an eight year old girl and the oldest patient a 60 year old 
man. Five of the 35 patients were older than 40 years and 22 patients 
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Figure 1: T1-weighted 3D-volume imaging with contrast (slide thickness 1.1 
mm, TR 2020 ms, TE 3.93 ms) shows filling defects consistent with thrombosis 
in the superior sagittal sinus and in the right transverse sinus (arrows).
Figure 2: T1-weighted 3D-volume imaging with contrast (slide thickness 1.1 
mm, TR 2020 ms, TE 3.93 ms) shows filling defects consistent with thrombosis 
in the superior sagittal sinus and in the right transverse sinus (arrows).
Figure 3: Diffusion Weighted Imaging (b1000) (slide thickness 5 mm, TR 
3200 ms, TE 94 ms) shows venous infarction in the right parietal lobe.
Figure 4: Susceptibility Weighted Imaging (SWI) (slide thickness 2 mm, 
TR 50 ms, TE 40 ms) shows hemorrhagic lesions in the right temporal lobe 
(asterisks) and accented vein drawings due to stasis.
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Hyperthyroidism and the coagulation system
Several studies of patients with hyperthyroidism have shown 
increased incidence of venous thromboembolic events [38], such as 
pulmonary embolism [39] and deep venous thrombosis [40]. Increased 
level of fT4 is associated with increased synthesis and secretion of 
factor VIII [40]. Abnormalities in the coagulation system, such as 
increased fibrinogen, von Willebrand factor (vWF), Plasminogen 
activator inhibitor 1 (PAI-1), coagulation factors VIII, IX and X and 
shorter activated partial thromboplastin time (APTT) have been 
found in hyperthyroid patients compared with euthyroid controls 
[41]. In a follow-up study, healthy volunteers were given levothyroxin 
and it was proved increased levels of fibrinogen, vWF, PAI-1 and 
coagulation factors VIII, IX and X [42]. These findings indicate that 
hypercoagulability and decreased fibrinolysis in hyperthyroidism is 
thyroxin-dependent.
A case study that supports the hypothesis of hypercoagulability 
reported death from CVT caused by thyroid crisis [25]. Another 
patient, also with life-threatening CVT and thyroid crisis, was treated 
with plasmapheresis which led to rapid reduction of fT3 and fT4 and 
removal of anti-phospholipid antibodies, with significant clinical 
improvement and normalization of factor VIII and vWF [29].
Other risk factors for CVT?
Our patient had heterozygous metylentetrahydrofolat reductase 
(MTHFR) gene. MTHFR mutation gene defects may lead to 
hyperhomocysteinemia. The prevalence of MTHFR mutations is found 
to be 14% but is only of clinical relevance when the gene is homozygote 
and homocysteine is elevated [43]. The heterozygous MTHFR gene was 
not regarded as a risk factor in our patient. One of the 35 patients in our 
overview had homozygous MTHFR gene and hyperhomocysteinemia 
[28]. 
Mechanical compression of veins from goiter has been mentioned 
[44] and a case study reports compression of truncus brachiocephalicus 
from goiter [45]. However, this was not suspected in our patient. 
It is not suspected that carbimazole increases the risk of venous 
thromboembolism [46]. 
Our patient had no problems tolerating a combination of desogestrel 
and ethinylestradiol before the development of Graves’ disease. Some 





Type of hyperthyroidism Coagulation deficiency and other risk factors
Schutta, 1991[8] 34/M Thyrotoxicosis Plasminogen deficiency, thrombocytosis,  chronic inflammatory lung disease




4 months after giving birth
Silburn, 1996 [10] 18/F GD None mentioned
Dulli, 1996 [11] 32/F Thyrotoxicosis Active protein C–resistance (APC-R)
De Schryver, 1999 [12] 32/M Thyrotoxicosis Protein C deficiency, positive Lupus anticoagulant
Verberne, 2000 [13] 28 /F GD Increased factor VIII
Dai, 2000 [14] 39 /M Hyperthyroidism None mentioned
Longe, 2000 [15] 18 / M 38 /M
Hyperthyroidism 
GD None mentioned
Ra, 2001 [16] 60 /M GD Protein C deficiency, increased fibrinogen
Maes, 2002 [17] 39 /F GD Increased factor VIII
Molloy, 2003 [18] 28 /F GD Heterozygous factor V Leiden mutation
Colleran, 2003 [19] 37/F GD None mentioned
Madronero-Vuelta, 2004 [20] 42 /F De Quervains thyroiditis Heterozygous pro-thrombin G20210A mutation
















Kasuga, 2006 [23] 39 /M Hyperthyroidism Increased factor VIII
Roch, 2006 [24] 25 / F GD Increased factor VIII
Nagumo, 2007 [25] 28 /F GD Protein C deficiency
Kim, 2008 [26] 23 /F GD/ thyrotoxicosis Increased factor VIII
Pekdemir, 2008 [27] 28 /M Hyperthyroidism None mentioned
Strada, 2008 [28] 29 /M Thyrotoxicosis Elevated homocysteine, homozygous MTHFR C677Tgene
Usami, 2009 [29] 34 /F Thyrotoxicosis
Gastroenteritis and dehydration, increased factor 
VIII, protein C deficiency, anti-phospholipid 
antibodies positive
Bensalah, 2011 [30] 23 /M GD None mentioned
Hermans, 2011 [31] 22 /F GD None mentioned
Van Eimeren, 2012 [32] 8 /F Hyperthyroidism Heterozygous factor V Leiden mutation
Knudsen-Baas, 2012 17 /F GD Heterozygous MTHFR gene
Hwang, 2012 [33] 31/M Hyperthyroidism Increased factor IX and XI
Merino, 2012 [34] 30/M Hyperthyroidism Increased factor VIII and von Willebrand factor Ag
Migeot, 2013 [35] 26/F GD Post-partum, increased factor VIII
Table 1: Overview of published cases from 1991 to 2013 of patients with cerebral venous thrombosis and hyperthyroidism.
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of the other cases in the literature with hyperthyroidism and CVT were 
certainly not caused by hormonal contraception as twelve patients were 
men and one of the females was eight years old. A Danish cohort study 
of more than 1.6 million women found low risks of thrombotic stroke 
and myocardial infarction with hormonal contraception, although 
there were slight differences concerning components and dosages [47]. 
It is possible that use of hormonal contraceptive contributed to the 
CVT in our patient, but we suspect Graves’ disease as the main cause.
Conclusions
The cause of CVT may be multi-factorial. A review of the literature 
shows several cases of CVT due to hyperthyroidism. Studies indicate 
that a high thyroxin level causes a hypercoagulable condition. We 
suspect severe Graves` disease as the main precipitating cause of life-
threatening CVT in a 17 year old girl with previously uncomplicated 
use of hormonal contraception. CVT should be suspected and MRI 
with venous angiography be performed when unusual headache alone 
or in combination with neurological deficits occurs in patients with 
hyperthyroidism. In case of CVT, blood screening for coagulation 
abnormalities is indicated. On the other hand, hyperthyroidism should 
be suspected in young patients with CVT. CVT and hyperthyroidism 
must be treated as soon as possible.
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